Burapitant

Burapitant is a drug used in the field of medicine for the treatment of chemotherapy-induced nausea and vomiting. It is classified as a neurokinin 1 receptor antagonist, which means it works by blocking the action of a chemical in the brain that triggers nausea and vomiting.

Pharmacology[edit | edit source]

Burapitant is a highly selective and potent neurokinin 1 receptor antagonist. It works by blocking the action of substance P, a neurotransmitter in the brain that plays a key role in the vomiting reflex. By inhibiting the binding of substance P to its receptor, burapitant can prevent nausea and vomiting.

Clinical Use[edit | edit source]

Burapitant is used in combination with other antiemetic medications for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic cancer chemotherapy. It is administered orally in the form of a capsule.

Side Effects[edit | edit source]

Like all medications, burapitant can cause side effects. The most common side effects include fatigue, constipation, and diarrhea. Less common side effects can include dizziness, headache, and abdominal pain.

Contraindications[edit | edit source]

Burapitant should not be used in patients with known hypersensitivity to the drug or any of its components. It should also be used with caution in patients with severe hepatic impairment, as the drug is extensively metabolized in the liver.